Исследование общей и специфической токсичности рекомбинантного ангиогенина человека

Abstract

Angiogenin exerted no toxic effects in acute toxicity tests, all animals successfully endured the maximally attainable dose 12 g/kg intragastrically. To assess the long-term/chronic toxicity, the gel-based composition containing 0.01 % of angiogenin was daily applied to the scarified skin areas of rats for 1 month. No significant changes or differences between the treated and control groups were detected by common biochemical, hematological and histological assays. No local irritating effects of 0.0025 % angiogenin gel were detected in appropriate tests using outbred chinchilla rabbits. Angiogenin did not cause neither sensibilization of guinea pigs in active cutaneous anaphylaxis test nor delayed hypersensitivity reaction in mice. No detectable immuno- and embryotoxicity of the preparation were observed. Angiogenin was proved to lack mutagenic and carcinogenic capabilities, as well as the capability of stimulating the tumor growth upon intratumoral administration. The tested preparation of angiogenin showed no toxic effects, including systemic, local irritating, sensibilizing and skin-resorptive ones, and, thus, recombinant human angiogenin is a safe pharmacological substance. 10.30906/2073-8099-2022-14-2-40-53